The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Clorgilin     N-[3-(2,4- dichlorophenoxy)propyl]-N- methyl...

Synonyms: CLORGYLINE, Clorgilina, Clorgiline, Chlorgyline, Clorgilinum, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Clorgiline


Psychiatry related information on Clorgiline


High impact information on Clorgiline


Chemical compound and disease context of Clorgiline


Biological context of Clorgiline


Anatomical context of Clorgiline

  • Following the infusion of clorgyline, the administration of serotonin produced significant decreases in glucose utilisation in cortical areas of between 12 and 33% and in the caudate nucleus of 16% [23].
  • In order to examine the relationship between thyroid status, the circadian system, and antidepressant drug response, the antidepressant drug clorgyline, a monoamine oxidase inhibitor (MAOI), was administered chronically to sham-operated or thyroparathyroidectomized rats [24].
  • In vivo inhibition of type A by clorgyline, and type B by (--)deprenyl, however, tended to decrease the specific activity of both types of MAO to a smaller extent in the female than in the male hypothalamus [25].
  • The binding of N-methyl(R)salsolinol to mitochondria was inhibited by clorgyline, a MOA-A inhibitor, but not by (-)deprenyl, an MAO-B inhibitor [26].
  • The numerical density of dense core vesicles in pinealocyte perikarya increased after treatment with clorgyline [27].

Associations of Clorgiline with other chemical compounds

  • However, the neurotoxicity of these two analogs can be prevented by pretreatment with a combination of deprenyl and the selective MAO-A inhibitor clorgyline at doses that are sufficient to almost completely inhibit both MAO-B and MAO-A activities [28].
  • Clorgyline, an inhibitor of monoamine oxidase type A, blocked the formation of oxidized glutathione [29].
  • Essentially all MAO activity in the noradrenergic cultures was inhibited by preincubation with 10(-8)-10(-9) M clorgyline, which indicated that this activity was primarily MAO-A [30].
  • Responses to intravenous clonidine, a possible central noradrenergic probe, were examined in patients with depression before and after treatment with clorgiline, a selective monoamine oxidase type A inhibitor [31].
  • To address these issues, hypothalamic temperature (Thy) was monitored telemetrically in hamsters treated with three antidepressant drugs: the monoamine oxidase inhibitor (MAOI), clorgyline; the 5HT reuptake inhibitor, fluoxetine; and the alkali metal, lithium [32].

Gene context of Clorgiline


Analytical, diagnostic and therapeutic context of Clorgiline

  • The regional distributions of monoamine oxidase (MAO) types A and B have been identified in human brain in vivo with intravenously injected 11C-labeled suicide enzyme inactivators, clorgyline and L-deprenyl, and positron emission tomography [37].
  • Values similar to this were obtained by clorgyline titration, and both methods gave values similar to those found with a [3H]harmaline binding assay [38].
  • Short term clinical trials have shown that clomipramine is generally more effective than amitriptyline, imipramine, desipramine, nortriptyline or clorgiline in reducing obsessive compulsive symptoms [39].
  • Acute and chronic effects of desipramine and clorgyline on alpha(2)-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study [40].
  • From these, the dose that increased BP by 30 mmHg (ED(30)) was computed for each rabbit before and after oral administration of clorgyline, 1 mg/kg for one week, tranylcypromine 10 mg/kg, once, moclobemide, 20 mg/kg 3 times and TV-3326, 26 mg/kg for 2 weeks [41].


  1. MPTP-induced duodenal ulcers in rat. Prevention by reuptake blockers for serotonin and norepinephrine, but not dopamine. Keshavarzian, A., Wibowo, A., Gordon, J.H., Fields, J.Z. Gastroenterology (1990) [Pubmed]
  2. L-dopa cytotoxicity to PC12 cells in culture is via its autoxidation. Basma, A.N., Morris, E.J., Nicklas, W.J., Geller, H.M. J. Neurochem. (1995) [Pubmed]
  3. Fenfluramine-induced suppression of food intake and locomotor activity is differentially altered by the selective type A monoamine oxidase inhibitor clorgyline. Aulakh, C.S., Hill, J.L., Wozniak, K.M., Murphy, D.L. Psychopharmacology (Berl.) (1988) [Pubmed]
  4. Central hypothermic effects of some analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridinium ion (MPP+). Satoh, N., Yonezawa, A., Tadano, T., Kisara, K., Arai, Y., Kinemuchi, H. Neurosci. Lett. (1987) [Pubmed]
  5. L-deprenyl confers specific protection against MPTP-induced Parkinson's disease-like movement disorder in the goldfish. Adeyemo, O.M., Youdim, M.B., Markey, S.P., Markey, C.J., Pollard, H.B. Eur. J. Pharmacol. (1993) [Pubmed]
  6. Effect of low-dose clorgyline on 24-hour urinary monoamine excretion in patients with rapidly cycling bipolar affective disorder. Linnoila, M., Karoum, F., Potter, W.Z. Arch. Gen. Psychiatry (1982) [Pubmed]
  7. Clorgyline-induced reduction in body temperature and its relationship to vigilance states in Syrian hamsters. Gao, B., Duncan, W.C., Wehr, T.A. Neuropsychopharmacology (1991) [Pubmed]
  8. Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats. Guillem, K., Vouillac, C., Azar, M.R., Parsons, L.H., Koob, G.F., Cador, M., Stinus, L. Eur. J. Neurosci. (2006) [Pubmed]
  9. A behavioural and neurochemical analysis of chronic and selective monoamine oxidase inhibition. O'Regan, D., Kwok, R.P., Yu, P.H., Bailey, B.A., Greenshaw, A.J., Boulton, A.A. Psychopharmacology (Berl.) (1987) [Pubmed]
  10. 5-HT1A-sensitive adenylyl cyclase of rodent hippocampal neurons: effects of antidepressant treatments and chronic stimulation with agonists. Varrault, A., Leviel, V., Bockaert, J. J. Pharmacol. Exp. Ther. (1991) [Pubmed]
  11. Isolated chromaffin cells from adrenal medulla contain primarily monoamine oxidase B. Youdim, M.B., Banerjee, D.K., Pollard, H.B. Science (1984) [Pubmed]
  12. Monoamine oxidase: an important intracellular regulator of gastrin release in the rat. Dial, E.J., Huang, J., Delansorne, R., Lichtenberger, L.M. Gastroenterology (1986) [Pubmed]
  13. Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Insel, T.R., Murphy, D.L., Cohen, R.M., Alterman, I., Kilts, C., Linnoila, M. Arch. Gen. Psychiatry (1983) [Pubmed]
  14. Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients. Pickar, D., Murphy, D.L., Cohen, R.M., Campbell, I.C., Lipper, S. Arch. Gen. Psychiatry (1982) [Pubmed]
  15. Mechanisms of toxicity and cellular resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium in adrenomedullary chromaffin cell cultures. Reinhard, J.F., Carmichael, S.W., Daniels, A.J. J. Neurochem. (1990) [Pubmed]
  16. Interactions among deprenyl, clorgyline and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on catecholamines in mice. Lee, E.H., Yang, Y.L., Chia, L.G., Kuo, J.S. Neurosci. Lett. (1994) [Pubmed]
  17. A role for serotonin in alpha-naphthylthiourea-induced pulmonary edema. Mais, D.E., Bosin, T.R. Toxicol. Appl. Pharmacol. (1984) [Pubmed]
  18. Treatment with clorgyline and pargyline differentially decreases clonidine-induced hypotension and bradycardia. Gutkind, J.S., Enero, M.A. Naunyn Schmiedebergs Arch. Pharmacol. (1984) [Pubmed]
  19. Characterization of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) binding sites in C57BL/6 mouse brain: mutual effects of monoamine oxidase inhibitors and sigma ligands on MPTP and sigma binding sites. Itzhak, Y., Mash, D., Zhang, S.H., Stein, I. Mol. Pharmacol. (1991) [Pubmed]
  20. Cloning of a novel monoamine oxidase cDNA from trout liver. Chen, K., Wu, H.F., Grimsby, J., Shih, J.C. Mol. Pharmacol. (1994) [Pubmed]
  21. Guinea pig striatum as a model of human dopamine deamination: the role of monoamine oxidase isozyme ratio, localization, and affinity for substrate in synaptic dopamine metabolism. Azzaro, A.J., King, J., Kotzuk, J., Schoepp, D.D., Frost, J., Schochet, S. J. Neurochem. (1985) [Pubmed]
  22. Reduced peripheral presynaptic adrenoceptor sensitivity following chronic antidepressant treatment in rats. Finberg, J.P., Tal, A. Br. J. Pharmacol. (1985) [Pubmed]
  23. Serotonin depression of local cerebral glucose utilisation after monoamine oxidase inhibition. Grome, J.J., Harper, A.M. J. Cereb. Blood Flow Metab. (1985) [Pubmed]
  24. The interaction of thyroid state, MAOI drug treatment, and light on the level and circadian pattern of wheel-running in rats. Duncan, W.C., Schull, J. Biol. Psychiatry (1994) [Pubmed]
  25. Gonadal influences on the sexual differentiation of monoamine oxidase type A and B activities in the rat brain. Vaccari, A., Caviglia, A., Sparatore, A., Biassoni, R. J. Neurochem. (1981) [Pubmed]
  26. Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells. Yi, H., Akao, Y., Maruyama, W., Chen, K., Shih, J., Naoi, M. J. Neurochem. (2006) [Pubmed]
  27. Effects of sympathicolytic and sympathicomimetic drugs on pineal ultrastructure in the domestic pig. Lewczuk, B., Przybylska-Gornowicz, B. J. Pineal Res. (1997) [Pubmed]
  28. Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Heikkila, R.E., Kindt, M.V., Sonsalla, P.K., Giovanni, A., Youngster, S.K., McKeown, K.A., Singer, T.P. Proc. Natl. Acad. Sci. U.S.A. (1988) [Pubmed]
  29. Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Spina, M.B., Cohen, G. Proc. Natl. Acad. Sci. U.S.A. (1989) [Pubmed]
  30. Differences in monoamine oxidase activity between cultured noradrenergic and cholinergic sympathetic neurons. Pintar, J.E., Breakefield, X.O., Patterson, P.H. Dev. Biol. (1987) [Pubmed]
  31. Dissociation of norepinephrine turnover from alpha-2 responses after clorgiline. Hauger, R.L., Scheinin, M., Siever, L.J., Linnoila, M., Potter, W.Z. Clin. Pharmacol. Ther. (1988) [Pubmed]
  32. Antidepressant drug-induced hypothalamic cooling in Syrian hamsters. Duncan, W.C., Johnson, K.A., Wehr, T.A. Neuropsychopharmacology (1995) [Pubmed]
  33. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. De Colibus, L., Li, M., Binda, C., Lustig, A., Edmondson, D.E., Mattevi, A. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  34. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. Lamensdorf, I., Youdim, M.B., Finberg, J.P. J. Neurochem. (1996) [Pubmed]
  35. Striatal dopamine metabolism in monoamine oxidase B-deficient mice: a brain dialysis study. Fornai, F., Chen, K., Giorgi, F.S., Gesi, M., Alessandri, M.G., Shih, J.C. J. Neurochem. (1999) [Pubmed]
  36. Modulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase after inhibiting monoamine oxidase-A. Cho, S., Duchemin, A.M., Neff, N.H., Hadjiconstantinou, M. Eur. J. Pharmacol. (1996) [Pubmed]
  37. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Fowler, J.S., MacGregor, R.R., Wolf, A.P., Arnett, C.D., Dewey, S.L., Schlyer, D., Christman, D., Logan, J., Smith, M., Sachs, H. Science (1987) [Pubmed]
  38. Cimoxatone is a reversible tight-binding inhibitor of the A form of rat brain monoamine oxidase. Fowler, C.J., Strolin Benedetti, M. J. Neurochem. (1983) [Pubmed]
  39. Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. McTavish, D., Benfield, P. Drugs (1990) [Pubmed]
  40. Acute and chronic effects of desipramine and clorgyline on alpha(2)-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study. Mateo, Y., Fernández-Pastor, B., Meana, J.J. Br. J. Pharmacol. (2001) [Pubmed]
  41. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits. Weinstock, M., Gorodetsky, E., Wang, R.H., Gross, A., Weinreb, O., Youdim, M.B. Neuropharmacology (2002) [Pubmed]
WikiGenes - Universities